# Oric Pharmaceuticals (ORIC) Stock Analysis: A Biotech with 91% Potential Upside

- Link: https://www.directorstalkinterviews.com/oric-pharmaceuticals-oric-stock-analysis-a-biotech-with-91-potential-upside/4121245670
- Published: 2026-03-20T11:33:55+00:00
- Author: Madison Wilson

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) has captured the attention of investors
in the biotechnology sector due to its promising clinical-stage developments and
significant potential for stock price appreciation. With a market capitalization
of $1.24 billion, Oric is strategically positioned within the healthcare sector,
focusing on innovative therapies to combat cancer resistance mechanisms.

Currently trading at $11.10, Oric’s stock shows a modest price change of $0.24 (
0.02%) amidst a 52-week range of $4.26 to $14.41. The stock’s potential upside of
91.27% is particularly noteworthy, as analysts have set a bullish target price range
between $15.00 and $25.00, with an average target of $21.23. This bullish sentiment
is further supported by 14 buy ratings and only one hold rating, underscoring robust
investor confidence in Oric’s future growth trajectory.

Oric’s valuation metrics reflect its status as a clinical-stage company, with its
Forward P/E ratio at -7.09 and EPS at -1.47, which is typical for a biotech firm
still in the development phase. The company’s return on equity stands at -41.27%,
and its free cash flow is reported at -$69.1 million, highlighting the capital-intensive
nature of its operations as it advances its pipeline products through clinical trials.

The company’s clinical stage product candidates, such as enozertinib (formerly ORIC-
114) and rinzimetostat (formerly ORIC-944), are at the forefront of its pipeline.
Enozertinib is under Phase 1b study as a potent EGFR inhibitor targeting exon 20
insertion mutations, while rinzimetostat is an allosteric inhibitor of the polycomb
repressive complex 2 for prostate cancer, also in Phase 1b study. Strategic collaborations
with industry giants like Bayer and Johnson & Johnson to evaluate ORIC-944 in combination
with leading AR inhibitors Nubeqa and Erleada illustrate Oric’s potential to enhance
treatment efficacy through innovative therapeutic combinations.

From a technical standpoint, Oric’s stock is trading just below its 50-day moving
average of $11.47 but above its 200-day moving average of $10.96, suggesting a stable
upward trend over the longer term. The Relative Strength Index (RSI) at 25.48 indicates
that the stock may be oversold, presenting a potential buying opportunity for savvy
investors looking to capitalize on market inefficiencies.

Oric Pharmaceuticals, founded in 2014 and headquartered in South San Francisco, 
California, continues to make strides in the biotechnology industry. Its focus on
addressing cancer resistance mechanisms, backed by strategic partnerships and a 
promising product pipeline, positions the company as an intriguing prospect for 
investors seeking exposure to innovative healthcare solutions. As Oric advances 
its clinical trials and leverages its collaborations, its stock presents an enticing
opportunity with substantial upside potential for those willing to navigate the 
inherent risks of biotech investments.

Share on: